< Back to search
Filter
1

Clonal Evolution in Follicular Lymphoma

for
Follicular Lymphoma
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03190928

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Boston MA, Hampton VA, Greenville NC, York PA,
Sponsor: Loxo Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06588478

Phase2, Recruiting

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

for
Hodgkin Lymphoma
Location: Columbus OH, Madison WI, Minneapolis MN
Sponsor: Veronika Bachanova

Sex: All

Age: 18+

Code: NCT03681561

Phase1, Phase2, Recruiting

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

for
Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin,
Location: Boston MA, New York NY, Stanford CA
Sponsor: Beth Israel Deaconess Medical Center

Sex: All

Age: 18+

Code: NCT06510361

Phase2, Recruiting

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

for
Hodgkin Lymphoma
Location: St. John's, Halifax, Sherbrooke, Montreal, Ottawa,
Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 18+

Code: NCT05180097

Phase2, Recruiting

Interested in new lymphoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

for
B Cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06213311

Phase2, Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

for
CNS Lymphoma, Primary Central Nervous System Lymphoma,
Location: San Francisco CA
Sponsor: James Rubenstein

Sex: All

Age: 18+

Code: NCT05351593

Phase1, Phase2, Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

for
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins,
Location: Dallas TX, Sacramento CA
Sponsor: Estrella Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT06343311

Phase1, Phase2, Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

for
B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL),
Location: New York NY, Philadelphia PA, Ottawa, Toronto,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06526793

Phase2, Recruiting

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

for
Follicular Lymphoma, Lymphoma
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05389293

Phase2, Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

for
Hematologic Malignancies, Waldenstroms Macroglobulinaemia,
Location: Hackensack NJ, East Brunswick NJ, Montreal, Ottawa,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04728893

Phase2, Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

for
Recurrent Diffuse Large B-Cell Lymphoma,
Location: Sacramento CA
Sponsor: University of California, Davis

Sex: All

Age: 18+

Code: NCT05052528

Phase1, Recruiting

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

for
Diffuse Large B-cell Lymphoma
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All

Age: 18+

Code: NCT06977711

Phase1, Recruiting

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

for
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type,
Location: Columbus OH
Sponsor: Lapo Alinari

Sex: All

Age: 18+

Code: NCT05755087

Phase1, Recruiting

Early Integration of Palliative and Supportive Care in Cellular Therapy

for
Leukemia, Lymphoma, Multiple Myeloma, Blood Cancer,
Location: Calgary
Sponsor: Alberta Health Services, Calgary

Sex: All

Age: 18+

Code: NCT05190653

Recruiting

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

for
Multiple Myeloma, Lymphoma
Location: Omaha NE
Sponsor: University of Nebraska

Sex: All

Age: 19+

Code: NCT05135351

Recruiting

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

for
Large B-cell Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06045247

Phase2, Recruiting

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

for
Acute Leukemia, Acute Lymphoblastic Lymphoma
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All

Age: 0+

Code: NCT06803745

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Moncton, Sherbrooke, Albany NY, Greenfield Park,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05947851

Phase3, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: Halifax, Shirley NY, New York NY, Albany NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase3, Recruiting